New clinical data reinforce Dupixent’s role in treating eosinophilic esophagitis and may support its long-term positioning in the indication.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) reported Dupixent Phase 4 trial results showing significant improvements in esophageal function and structural disease markers in eosinophilic esophagitis (EoE). The data, presented at Digestive Disease Week 2026, may strengthen confidence in Dupixent’s clinical profile and durability as a leading treatment in this chronic condition.
Key Investor Takeaways
- Regeneron (NASDAQ:REGN) and partner Sanofi reported positive Phase 4 data, reinforcing Dupixent’s efficacy in EoE.
- The trial showed statistically significant improvements in esophageal function and disease structure versus placebo.
- High histological remission rates (59% vs. 4%) could support continued adoption in clinical practice.
- Dupixent remains the only approved biologic for EoE, strengthening its competitive positioning.
- Longer-term data and real-world adoption may influence the commercial trajectory in this indication.
Press Release Overview
The REMODEL Phase 4 trial evaluated Dupixent in 69 adults with eosinophilic esophagitis, comparing weekly 300 mg dosing (n=46) to placebo (n=23) over 24 weeks.
Key findings included:
- A 1.28 mm improvement in esophageal distensibility versus a slight decline in the placebo group, meeting the primary endpoint (p<0.05).
- A 4.89-point reduction in abnormal endoscopic findings compared to a minimal increase in placebo (p<0.0001).
- Improvements in histological disease severity and extent, with statistically significant reductions versus placebo (p<0.0001).
- 59% of patients achieved histological remission compared to 4% with placebo.
The company stated that safety results were consistent with Dupixent’s known profile, with no serious adverse events reported.
The ongoing study includes a longer-term extension phase, with additional data expected through week 128.
Why This Matters for Investors
The Phase 4 results add incremental evidence supporting Dupixent’s clinical benefit in EoE, particularly in improving esophageal function and structural disease changes. This may reinforce the drug’s role as a standard-of-care treatment in this indication.
As Dupixent is already approved for EoE and multiple other conditions, continued positive data could help sustain physician confidence and support broader adoption. The high remission rates and improvements in disease markers may also strengthen its competitive moat, given the limited number of alternative biologic treatments.
However, the commercial impact may depend on long-term outcomes, payer dynamics, and how future therapies in development perform. While the data are supportive, investors may look for evidence of sustained efficacy and real-world uptake.
What to Watch For Next
- Additional long-term data from the REMODEL trial extension phase
- Updates on Dupixent sales growth in EoE and related indications
- Any new competing therapies entering the EoE market
- Physician adoption trends and real-world effectiveness data
- Regulatory or label expansion updates tied to further clinical findings
Conclusion
The latest Dupixent Phase 4 trial results reinforce its clinical profile in eosinophilic esophagitis, adding to its established position in the market. While the data support continued use and potential adoption, investors may focus on long-term outcomes and commercial execution to assess the broader impact.